Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?

Journal of medical virology - 1 Oct 2011

Champenois Karen, Baras Agathe, Choisy Philippe, Ajana Faiza, Melliez Hughes, Bocket Laurence, Yazdanpanah Yazdan

Abstract excerpt

The HIV-1 protease L76V mutation has been described recently as conferring high-level resistance to lopinavir/ritonavir (LPV/r). The aim was to identify the factors and particularly protease mutations associated with the presence of L76V in treatment-experienced patients infected with HIV-1 who have failed virologically an LPV/r-based antiretroviral therapy regimen. This is a retrospective exploratory study....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Ritonavir

Share to RNA, Viral

Source

Identifiers

PMID: 21755502
DOI: 10.1002/jmv.22161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?PMID 21755502Read ↗

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.Semantic proximity Read ↗

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.Semantic proximity Read ↗

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.Semantic proximity Read ↗

Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.Semantic proximity Read ↗

HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience.Semantic proximity Read ↗

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.Semantic proximity Read ↗

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.Semantic proximity Read ↗

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.Semantic proximity Read ↗

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.Semantic proximity Read ↗

A virological perspective on resistance in highly treatment-experienced patients.Semantic proximity Read ↗

Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.Semantic proximity Read ↗

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.